MarketCap
Facebook
X
Telegram
Genmab A/S Revenue | GMAB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Genmab A/S
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 10.1 B | 5.37 B | 3.03 B | 2.37 B | 1.82 B | 1.13 B | 850 M | 664 M | 485 M | 351 M |
Annual performance
Select metrics to display
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 B | 351 M | 2.62 B |
Quarterly Revenue Genmab A/S
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 21.5 B | 5.4 B | 16.5 B | 4.2 B | - | - | 3.16 B | - | - | - | 1.97 B | - | - | - | 5.45 B | - | - | - | 774 M | - | - | - | 510 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in DKK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.5 B | 510 M | 6.61 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Idera Pharmaceuticals
IDRA
|
4.86 M | - | -23.04 % | $ 26.6 M |  USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.5 B | $ 40.03 | 1.57 % | $ 45.8 B |  Israel |
 |
Collegium Pharmaceutical
COLL
|
205 M | $ 23.21 | 1.09 % | $ 735 M | USA |
 |
NanoString Technologies
NSTG
|
127 M | - | -37.43 % | $ 5.1 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
761 M | $ 87.25 | 1.62 % | $ 9.06 B | USA |
 |
TG Therapeutics
TGTX
|
616 M | $ 54.79 | 1.14 % | $ 7.91 B | USA |
 |
Humanigen
HGEN
|
2.51 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
62.8 M | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
30 M | - | - | $ 59.7 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
882 K | $ 4.0 | -1.36 % | $ 53.3 M | USA |
 |
Sierra Oncology
SRRA
|
300 K | - | -0.05 % | $ 1.34 B |  Canada |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
13.1 M | $ 5.31 | 2.42 % | $ 45.2 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
351 M | $ 4.16 | 2.97 % | $ 339 M | USA |
 |
Tenax Therapeutics
TENX
|
49.3 K | $ 1.65 | -4.07 % | $ 64.7 M | USA |
 |
Vaccinex
VCNX
|
601 K | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
5 K | - | -19.68 % | $ 18.4 M | Canada |
 |
Taysha Gene Therapies
TSHA
|
9.77 M | $ 4.0 | 0.88 % | $ 1.28 B | USA |
 |
Jounce Therapeutics
JNCE
|
82 M | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
42.3 M | - | - | $ 69.7 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
3.51 M | $ 49.0 | -0.79 % | $ 4.41 B |  Schweiz |
 |
UroGen Pharma Ltd.
URGN
|
110 M | $ 34.05 | -1.29 % | $ 1.64 B | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
469 K | - | -11.43 % | $ 502 K | USA |
 |
United Therapeutics Corporation
UTHR
|
3.18 B | $ 593.02 | 0.94 % | $ 26.3 B | USA |
 |
Vericel Corporation
VCEL
|
276 M | $ 42.99 | 1.08 % | $ 2.16 B | USA |
 |
Veracyte
VCYT
|
517 M | $ 48.22 | 0.61 % | $ 3.79 B | USA |
 |
Champions Oncology
CSBR
|
59.4 M | $ 4.82 | 2.12 % | $ 66.7 M | USA |
 |
Mersana Therapeutics
MRSN
|
40.5 M | - | - | $ 3.56 B | USA |
 |
Vir Biotechnology
VIR
|
68.6 M | $ 11.02 | 4.27 % | $ 1.53 B | USA |
 |
Viking Therapeutics
VKTX
|
10.7 K | $ 24.23 | -0.72 % | $ 2.73 B | USA |
 |
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | USA |
 |
Cabaletta Bio
CABA
|
0.006 | $ 1.34 | -9.18 % | $ 135 M | USA |
 |
CytomX Therapeutics
CTMX
|
76.2 M | $ 2.23 | -4.09 % | $ 308 M | USA |
 |
Vanda Pharmaceuticals
VNDA
|
216 M | $ 3.95 | -1.62 % | $ 233 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
83.2 K | - | - | $ 717 K | USA |
 |
Verrica Pharmaceuticals
VRCA
|
35.6 M | $ 3.4 | -3.68 % | $ 36.2 M | USA |
 |
Viridian Therapeutics
VRDN
|
70.8 M | $ 23.31 | 4.2 % | $ 2.37 B | USA |
 |
G1 Therapeutics
GTHX
|
82.5 M | - | - | $ 370 M | USA |
 |
Verastem
VSTM
|
30.9 M | $ 9.9 | -1.34 % | $ 686 M | USA |
 |
VistaGen Therapeutics
VTGN
|
1.27 M | $ 0.17 | -3.9 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
40.4 M | $ 1.76 | 0.86 % | $ 103 M | USA |
|
Amryt Pharma plc
AMYT
|
223 M | - | - | $ 621 M | Britain |
|
Cerevel Therapeutics Holdings
CERE
|
2.72 M | - | - | $ 7.29 B | USA |